Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
Shyna Mae Deang

Novo Nordisk's Future Vision on 'Weight Loss' Wins Scientists, Tests Wall Street's Patience

Novo Nordisk’s long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns. (Credit: novonordisk/Instagram)

The Danish pharmaceutical giant Novo Nordisk, led by new CEO Maziar Mike Doustdar, is spearheading a radical transformation of its long-term research and development strategy.

The company is moving 'beyond the scale' to reposition its flagship GLP-1 molecules, such as semaglutide, as comprehensive treatments for MASH (liver disease), chronic kidney disease, and cardiovascular health, rather than just weight-loss aids.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.